Q3 Revenue Climbs 7% to $1.38B as Bausch + Lomb Swings to $32M Profit
BLCO sits 21% above its 52-week low of $14.44.
Summary
Bausch + Lomb posted Q3 revenue of $1.375B, up 7% year over year (about 8% in constant currency), and swung to net income of $32M from a $28M loss a year ago, with EPS of 9c and adjusted EPS of 34c. Adjusted EBITDA jumped to $325M from $243M and operating income rose to $155M from $95M, so the profit improvement is showing up in the core numbers, not just adjustments. Growth was broad: Vision Care revenue of $774M rose 5% on daily SiHy and ULTRA lenses, while Pharma revenue of $367M climbed 11% on MIEBO and international pharma. The company sees 2026 revenue of $5.45B-$5.55B. This follows the July 29 10-Q, when Q2 revenue of $1.394B rose 9% and the company raised full-year guidance — Q3 keeps that streak alive with a fourth straight quarter of meeting Investor Day targets. The open question is the planned separation from Bausch Health and whether management gives explicit guidance metrics on the call; the interim CEO handoff after Brent Saunders' October departure adds execution risk to that timeline.
At the time of this announcement, BLCO was trading at $17.43 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $14.44 to $18.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.